Safety and tolerability of Evusheld in patients with CVID: The Mayo Clinic experience.

Squire, Jacqueline D; Pitlick, Mitchell M; Freeman, Catherine M; Joshi, Avni Y.

Afiliação

Squire JD; Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic, Jacksonville.
Pitlick MM; Division of Allergic Diseases, Mayo Clinic, Rochester.
Freeman CM; Division of Allergy, Asthma and Clinical Immunology, Mayo Clinic, Scottsdale.
Joshi AY; Division of Pediatric Allergy and Immunology, Mayo Clinic Children's Center, Rochester.

J Allergy Clin Immunol Glob ; 2(2): 100081, 2023 May.

Article em En | MEDLINE | ID: mdl-36777105

Palavras-chave

COVID; COVID-19, Coronavirus disease 2019; CVID; CVID, Common variable immunodeficiency; ED, Emergency department; EUA, Emergency use authorization; Evusheld; SAE, Serious adverse event; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; immunocompromise

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article